KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 11.49% to $48.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.2 million through Dec 2025, up 11.49% year-over-year, with the annual reading at $48.2 million for FY2025, 11.49% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $48.2 million at Xenon Pharmaceuticals, up from $45.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $48.2 million in Q4 2025, with the low at $43.2 million in Q4 2024.